NCT00077116View on ClinicalTrials.gov

Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

November 30, 2006

Conditions
LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

busulfan

DRUG

cyclophosphamide

DRUG

cytarabine

DRUG

gemtuzumab ozogamicin

DRUG

idarubicin

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

peripheral blood stem cell transplantation

RADIATION

radiation therapy

Trial Locations (9)

1000

Institut Jules Bordet, Brussels

1200

Cliniques Universitaires Saint-Luc, Brussels

8000

AZ Sint-Jan, Bruges

8800

H. Hartziekenhuis - Roeselaere., Roeselare

D-69117

Ruprecht - Karls - Universitaet Heidelberg, Heidelberg

1091 HA

Onze Lieve Vrouwe Gasthuis, Amsterdam

2300 CA

Leiden University Medical Center, Leiden

NL-6500 HB

Universitair Medisch Centrum St. Radboud - Nijmegen, Nijmegen

CH-4031

Universitaetsspital-Basel, Basel

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT00077116 - Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter